Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pillar Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,641,862

137 payments

Through program year 2025, Pillar Clinical Research is reported as receiving $1,641,862 in research payments, across 137 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,118,154 19
2024 Research $4,656 15
2023 Research $77,946 29
2022 Research $39,749 14
2021 Research $93,144 26
2020 Research $248,565 23
2019 Research $59,648 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $1,110,074 4 payments
  2. Biogen, Inc. $235,657 6 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $175,649 7 payments
  4. Biohaven Pharmaceuticals, Inc. $49,512 2 payments
  5. Boehringer Ingelheim International GmbH $45,335 41 payments
  6. Indivior Inc. $11,508 25 payments
  7. Boehringer Ingelheim Pharma GmbH & Co.KG $5,615 1 payment
  8. ACADIA Pharmaceuticals Inc $2,081 1 payment
  9. Sumitomo Pharma America, Inc. $1,842 26 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $1,530 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $1,040,915 1 payment
  2. A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $235,657 6 payments
  3. Adjunctive Computerized Cognitive Training CCT $101,355 5 payments
  4. PoCP study Phase Ib of NR2B modulation in MDD $74,789 3 payments
  5. A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Manic Episodes or Mixed Manic Episodes in Individuals with Bipolar-I Disorder and Inadequate Response to Lithium, Valproate, or Lamotrigine $57,213 1 payment
  6. Phase 1: Open-Label 8-Week Safety Study of Oral Zavegepant (BHV-3500) in Normal Healthy Subjects $51,042 3 payments
  7. PoC in Prevention of Relapse $31,544 3 payments
  8. BI 425809 Adjunctive Computerized Cognitive Training (CCT) $18,912 38 payments
  9. An Open-Label, Multicentre Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Repeated Doses of Indv-6001 in Adults With Moderate to Severe Opioid Use Disorder $11,508 25 payments
  10. A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $9,206 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record